| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Deep eutectic solvent (DES)
|
|---|---|
| References | |
| Additional Infomation |
Acyl-CoA synthase 4 (ACSL4) is an isoenzyme of the fatty acid ligase-CoA family, involved in arachidonic acid metabolism and steroid production. ACSL4 participates in the aggressive development of breast and prostate cancer by regulating multiple signal transduction pathways. This study, using bioinformatics analysis, found similarities in ACSL4 gene expression and proteomic features in tumor samples from breast and prostate cancer patients to those observed in cell models. However, no fully validated ACSL4 inhibitors have been reported, hindering comprehensive exploration of this potential target and its therapeutic applications in cancer and steroid inhibition. This study identified an ACSL4 inhibitor, PRGL493, using an ACSL4 homology model and a molecular docking-based virtual screening method. PRGL493 was subsequently chemically characterized by NMR and mass spectrometry. The inhibitory activity of this compound was confirmed by inhibiting the conversion of arachidonic acid to arachidonicyl-CoA using recombinant enzymes and cell models. The compound inhibited cell proliferation and tumor growth in breast and prostate cancer cells and animal models, and enhanced the sensitivity of tumor cells to chemotherapy and hormone therapy. In addition, PGRL493 also inhibited de novo steroid synthesis in mouse testicular and adrenal cells and prostate tumor cells. This work provides proof of concept for the potential application of PGRL493 in clinical practice. At the same time, these findings may be crucial for the treatment of controlling the growth and drug resistance of ACSL4-expressing steroid-dependent tumors. [1]
|
| Molecular Formula |
C8H12O7
|
|---|---|
| Molecular Weight |
220.176683425903
|
| Exact Mass |
220.058
|
| CAS # |
53798-97-3
|
| PubChem CID |
253213
|
| Appearance |
White to off-white solid powder
|
| Density |
1.378g/cm3
|
| Boiling Point |
405.1ºC at 760 mmHg
|
| Flash Point |
162.6ºC
|
| Index of Refraction |
1.484
|
| LogP |
-1.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
15
|
| Complexity |
272
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC(C(=O)OC)(CC(=O)O)CC(=O)OC
|
| InChi Key |
OMIHCBSQSYMFDP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H12O7/c1-14-6(11)4-8(13,3-5(9)10)7(12)15-2/h13H,3-4H2,1-2H3,(H,9,10)
|
| Chemical Name |
3-hydroxy-5-methoxy-3-methoxycarbonyl-5-oxopentanoic acid
|
| Synonyms |
53798-97-3; Dimethyl Citric acid; 3-hydroxy-5-methoxy-3-methoxycarbonyl-5-oxopentanoic acid; (R)-3-Hydroxy-5-methoxy-3-(methoxycarbonyl)-5-oxopentanoic acid; 1,2-dimethyl citrate; 1,2-Dimethyl 2-hydroxy-1,2,3-propanetricarboxylate; NSC75822; Compound NP-017933
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (454.17 mM)
H2O: 5 mg/mL (22.71 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5417 mL | 22.7087 mL | 45.4174 mL | |
| 5 mM | 0.9083 mL | 4.5417 mL | 9.0835 mL | |
| 10 mM | 0.4542 mL | 2.2709 mL | 4.5417 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
